Effectiveness and safety of tocilizumab, an anti–interleukin-6 receptor antibody, in 342 Japanese patients with multicentric Castleman disease: a 3-year, prospective, observational study
The effectiveness and safety of tocilizumab in Japanese patients with MCD was confirmed for up to 3 years, without new safety concerns.
Authors
- Seiji Hayashi (ORCID: https://orcid.org/0000-0001-7465-6166)
- Yuichi Kawata
- Takeshi Johkoh (ORCID: https://orcid.org/0000-0003-1237-2349)
- Shiro Ohshima (ORCID: https://orcid.org/0000-0003-1607-3979)
- Miho Murakami
- Takahiro Kakehi
- Shinichi Matsuda (ORCID: https://orcid.org/0000-0003-1822-1090)
- Norihiro Nishimoto (ORCID: https://orcid.org/0000-0001-8241-8010)
- Shin-ichi Nakatsuka
- Masao Mizuki (ORCID: https://orcid.org/0009-0004-7056-4992)
- Misato Hashizume
Institutions
- Osaka City University (JP)
- Osaka International Cancer Institute (JP)
- Chugai Pharma (United States) (US)
- Kansai Rosai Hospital (JP)
- Osaka Nishi Clinic (JP)
- Osaka Minami Medical Center (JP)
- Japan Society of Chemotherapy (JP)
- Osaka University Hospital (JP)
- NHO Kinki Chuo Chest Medical Center (JP)
- Osaka City University Hospital (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2025-10-20
- DOI
- https://doi.org/10.1093/mr/roaf100
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00